Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Low Molecular Weight Heparin on Survival of Stage I, II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.

Trial Profile

Effect of Low Molecular Weight Heparin on Survival of Stage I, II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TILT
  • Most Recent Events

    • 27 Sep 2018 Results published in the European Respiratory Journal.
    • 15 Sep 2016 Last checked against ClinicalTrials.gov record.
    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top